Latest Parkin Stories

OXFORD, England, May 23, 2011 /PRNewswire-FirstCall/ -- - Six-Month Data From Third Cohort Presented at ASGCT 14th Annual Meeting - - Highest Efficacy Results to Date With 43% Average Motor Function Improvement - Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), a leading gene therapy company, announces that new data from the on-going Phase I/II trial of ProSavin(R) for the treatment of Parkinson's disease (PD) were presented at the American Society...

Restoring brain function and protecting brain cells of people suffering from Parkinson's disease is the goal of a new double blind Phase 2b study evaluating CERE-120. Baylor College of Medicine is one of 11 major U.S. medical centers currently enrolling patients.This study is testing the safety and potential benefits of an enhanced CERE-120 dosing regimen targeting two brain areas affected by Parkinson's disease. CERE-120 is a gene therapy product that delivers the gene for the neurotrophic...

MIAMI, April 5, 2011 /PRNewswire/ -- A recent nationwide survey conducted by the National Parkinson Foundation (NPF) revealed 60 percent of Americans would wait to see their doctor if they were experiencing consistent regular tremors -- despite the fact that most of those surveyed (81%) recognized that tremors are an early warning sign of Parkinson's disease (PD). Although men suffer from Parkinson's 1.5-2 times more than females, the men surveyed were more likely to adopt a wait and see...

As Parkinson's Awareness Month gets underway, a Canadian-led international study is providing important new insight into Parkinson's disease and paving the way for new avenues for clinical trials. The study, led by Dr. Michael Schlossmacher in Ottawa, provides the first link between the most common genetic risk factor for Parkinson's and the hallmark accumulation of a protein called alpha-synuclein within the brains of people with Parkinson's. It is published in the most recent edition of the...

Researchers at Mount Sinai School of Medicine have discovered a way that mutations in a gene called LRRK2 may cause the most common inherited form of Parkinson's disease. The study, published online this month in the journal Public Library of Science, shows that upon specific modification called phosphorylation, LRRK2 protein binds to a family of proteins called 14-3-3, which has a regulatory function inside cells. When there is a mutation in LRRK2, 14-3-3 is impaired, leading to Parkinson's....

(Ivanhoe Newswire) -- Researchers have discovered PARIS -- the protein -- may be responsible for the most common form of Parkinson's disease (PD).PD affects about 1 million older Americans. Previous research has shown a protein known as "parkin" protects brain cells by "tagging" certain toxic elements for natural destruction. Mutations of the parkin gene cause rare forms of PD that runs in families, but researchers were unclear about parkin's role in sporadic, late-onset...

Enrollment is well under way in a new double-blind Phase 2b study evaluating CERE-120 in Parkinson's disease patients. Baylor College of Medicine is one of eleven major U.S. medical centers currently enrolling patients. CERE-120 is a gene therapy product that delivers the gene for the neurotrophic factor neurturin to degenerating or dying dopamine neurons in the hopes it will restore function and protect brain cells from further damage.This study is testing the safety and potential benefits...

A protein pathway that may hold the secret to understanding Parkinson's disease has been discovered and explained by Iowa State University researchers.Anumantha Kanthasamy, a distinguished professor of biomedical sciences and the W. Eugene and Linda R. Lloyd Endowed Chair in Neurotoxicology at the ISU College of Veterinary Medicine, has been working to understand the complex mechanisms of the disease for more than a decade. He believes this recent discovery offers hope for the cure.The...

SAN DIEGO, Feb. 15, 2011 /PRNewswire/ -- Ceregene, Inc., a biopharmaceutical company, reported today that its scientists and collaborators have published new experimental findings in support of its Parkinson's disease program which appeared as the lead article in the current issue of Movement Disorders (the official journal of the Movement Disorders Society). The publication reports the first evidence that gene transfer can provide targeted expression of a neurotrophic factor, i.e.,...

Investigators Build a Case Linking Chemical DOPAL to IllnessIn new research from Saint Louis University, investigators have found evidence that a toxin produced by the brain is responsible for the series of cellular events that lead to Parkinson's disease. The study, published in PLoS One, found that the brain toxin DOPAL plays a key role in killing the dopamine neurons which trigger the illness.In earlier research, Saint Louis University investigators found that DOPAL seemed to be...